Leerink analyst David Risinger notes AbbVie (ABBV) announced on November 11 that emraclidine’s pivotal Phase 2 trials, EMPOWER-1 and EMPOWER-2, did not meet their primary endpoints. The firm argues that this outcome is a clear positive positive for Bristol Myers (BMY) because its recently approved schizophrenia treatment Cobenfy will not face competition from emraclidine. Leerink has a Market Perform rating on AbbVie’s shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.